MAPT and early-onset autosomal dominant Alzheimer disease: Multiple studies have shown that the treatment targeting pathological Tau is a promising direction for Alzheimer’s disease research and OPTN has great potential in clearing pathological Tau and alleviating neurotoxicity [21, 22].